Form 4: Dyne Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations

Dyne Therapeutics' Chief Scientific Officer, Oxana Beskrovnaya, sold shares to cover tax obligations related to vested restricted stock units.

Summary

• Oxana Beskrovnaya, the Chief Scientific Officer of Dyne Therapeutics, sold 2,334 shares of common stock on December 11, 2024.
• The shares were sold to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) granted on December 10, 2021, and December 9, 2022.
• The sale was automatic and not a discretionary trade by the Reporting Person, as it was part of a pre-existing agreement.
• The shares were sold at a weighted average price of $28.12, with individual transactions ranging from $27.76 to $28.71.
• The reporting person also holds 165,922 unvested RSUs.

Sentiment

Score: 5

Explanation: The document describes a routine transaction related to executive compensation and tax obligations, which is neither positive nor negative for the company's overall outlook.

Industry Context

This type of transaction is common for executives who receive stock-based compensation, as they often need to sell shares to cover the associated tax liabilities.

Comparison to Industry Standards

• Many biotechnology companies use restricted stock units as part of their executive compensation packages.
• It is standard practice for executives to sell shares to cover tax obligations when these units vest.
• The automatic sale mechanism is a common way to ensure compliance with insider trading regulations.

Stakeholder Impact

• The sale of shares by the Chief Scientific Officer has a minimal impact on shareholders as it is a routine transaction.

Key Dates

Keywords

Dyne Therapeutics, stock sale, restricted stock units, tax obligations, insider trading, executive compensation